Jonathan Odeh

Business Development & Strategy Manager

Jonathan combines formal education in pharmaceutical outcomes, Pharmacoeconomics, economics, and pharmaceutical sciences with practical experience spanning radiopharmaceutical production, cyclotron facility development, healthcare strategy, and market access. He has completed a Master of Science in Pharmacy in Pharmaceutical Outcomes and Policy, with a concentration in Applied Pharmacoeconomics, at the University of Florida College of Pharmacy. He also holds a Bachelor of Arts in Economics with a minor in Pharmaceutical Sciences from The Ohio State University.

Jonathan began his work with Cyclomedical through a healthcare consulting internship, during which he conducted a cost-effectiveness analysis comparing F-18 FDG PET/CT with standard cancer detection and treatment protocols. He later completed an intensive radiopharmaceutical training program at Cyclomedical’s Al Ain facility in the UAE, gaining experience in PET radiotracer production, synthesis, quality control, cyclotron operations, radiochemistry equipment, GMP readiness, and radiopharmaceutical supply-chain logistics. His experience includes F-18, N-13 Ammonia, and Ga-68 radiopharmaceuticals used across oncology, neurology, and cardiology.

In his current role, Jonathan supports the development and expansion of radiopharmaceutical and cyclotron projects through feasibility studies, financial modeling, market analysis, regulatory planning, procurement coordination, and operational strategy. He has also prepared Health Technology Assessments and business cases for diagnostic and therapeutic radiopharmaceuticals, including Flurpiridaz, Flutemetamol, Lu-177 DOTA-TATE, and Lu-177 PSMA. His broader healthcare experience includes radiology research at the University of Chicago and institutional healthcare and pharmaceutical research for major investment organizations. Jonathan’s work focuses on connecting clinical and technical capabilities with commercially sustainable strategies for expanding access to molecular imaging and radiopharmaceutical technologies.

`